Compare stocks

PHG vs TLSI

KONINKLIJKE PHILIPS N.V. and TriSalus Life Sciences, Inc. Common Stock

Compare the businesses

KONINKLIJKE PHILIPS N.V.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides diagnostic imaging solutions, includes magnetic resonance imaging; X-ray systems; and computed tomography (CT) systems and software comprising detector-based spectral CT solutions; ultrasound imaging solutions focused on diagnosis, treatment planning and guidance for cardiac, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional X-ray systems and software solutions; and interventional image devices and software to aid in the diagnosis, navigation, treatment, and confirmation in minimally invasive interventional coronary, peripheral vascular, and hearth rhythm management procedures. The company also offers acute patient management solutions; emergency care solutions; patient care management in ambulatory and home care; sleep and respiratory care solutions; and vendor-agnostic software solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental and women's health solutions; and grooming and beauty products and solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Open PHG dashboard ↗

TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Open TLSI dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗